Shakil Aslam Buys 35,000 Shares of Talphera (NASDAQ:TLPH) Stock

Talphera, Inc. (NASDAQ:TLPH) insider Shakil Aslam acquired 35,000 shares of Talphera stock in a transaction dated Thursday, February 12th. The shares were bought at an average price of $0.81 per share, with a total value of $28,350.00. Following the transaction, the insider directly owned 83,178 shares in the company, valued at approximately $67,374.18. The trade was a 72.65% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Talphera Price Performance

NASDAQ TLPH opened at $0.78 on Friday. The firm’s fifty day moving average price is $1.00 and its 200 day moving average price is $0.99. Talphera, Inc. has a 12 month low of $0.38 and a 12 month high of $1.57. The company has a market capitalization of $36.20 million, a price-to-earnings ratio of -2.04 and a beta of 0.46.

Institutional Investors Weigh In On Talphera

Hedge funds have recently made changes to their positions in the business. Group One Trading LLC grew its holdings in shares of Talphera by 3,224.0% during the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after buying an additional 29,500 shares during the last quarter. Virtu Financial LLC acquired a new stake in Talphera during the 3rd quarter worth approximately $29,000. Mariner LLC lifted its position in Talphera by 132.0% during the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after acquiring an additional 33,000 shares during the period. Persistent Asset Partners Ltd purchased a new position in shares of Talphera in the 4th quarter valued at approximately $42,000. Finally, Dauntless Investment Group LLC acquired a new position in shares of Talphera in the third quarter valued at approximately $89,000. Institutional investors and hedge funds own 37.67% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on TLPH. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. Wall Street Zen raised Talphera to a “hold” rating in a research report on Saturday, November 1st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Talphera currently has an average rating of “Hold” and a consensus target price of $6.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.